<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518163</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/279/7/19</org_study_id>
    <nct_id>NCT04518163</nct_id>
  </id_info>
  <brief_title>Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa</brief_title>
  <official_title>Bakri Balloon Tamponade Plus Intravenous Tranexamic Acid During Cesarean Delivery for Placenta Previa: a Randomized Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective to investigate the effect of adjunctive intravenous tranexamic acid (TA) on blood&#xD;
      loss during cesarean section (CS) in patients with placenta previa undergone Bakri balloon&#xD;
      tamponade&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placenta previa (PP) is an obstetric condition that is closely linked with massive obstetric&#xD;
      hemorrhage with a varied incidence about once in every 200 live births. It is considered one&#xD;
      of the causes of the increased need for blood transfusion and cesarean hysterectomy. PPH due&#xD;
      to PP typically starts during cesarean section (CS) in the placental bed, at the lower&#xD;
      uterine segment mostly after placental separation. Proceeding for cesarean hysterectomy can&#xD;
      be the only effective line of management in spite of the associated high morbidity rate.&#xD;
&#xD;
      Tranexamic acid is a lysine analog which acts as an antifibrinolytic via competitive&#xD;
      inhibition of the binding of plasmin and plasminogen to fibrin. The rationale for its use in&#xD;
      the reduction of blood loss depending on the implication of the coagulation and fibrinolysis&#xD;
      processes implicated in the control of PPH. However, concerns about possible thromboembolic&#xD;
      events with parenteral administration of TA have stimulated increasing interest in its&#xD;
      topical use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind randomized controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>mean Blood loss after placental separation</measure>
    <time_frame>30 minutes</time_frame>
    <description>by using weight of soaked towels (weight of soaked towel - weight of dry towel) and amount of blood in suction set</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with postpartum hemorrhage</measure>
    <time_frame>12 hours</time_frame>
    <description>number pf participants with blood loss &gt; 1000ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participant needed of extra surgical maneuvers</measure>
    <time_frame>30minutes</time_frame>
    <description>Calculation of the number of participant needed of extra surgical maneuvers like internal iliac artery ligation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Placenta Previa</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus 1gm tranexamic acid by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally plus saline by intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Intravenous 1 gm tranexamic acid in 100 ml saline by slow infusion before skin incision</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>TA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to TA</intervention_name>
    <description>Intravenous 110 ml saline by slow infusion before skin incision</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bakri Balloon</intervention_name>
    <description>Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>BBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women undergoing elective cesarean delivery for complete placenta previa which not&#xD;
             respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic&#xD;
             sutures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with the high possibility of morbid adherent placenta&#xD;
&#xD;
          -  those presented with severe antepartum hemorrhage&#xD;
&#xD;
          -  Patients with cardiac, hepatic, renal, or thromboembolic disease;&#xD;
&#xD;
          -  hypersensitivity or contraindications of use of tranexamic acid&#xD;
&#xD;
          -  patient refuses to consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women undergoing elective cesarean delivery for complete placenta previa</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nahla w Shady, md</last_name>
    <role>Study Chair</role>
    <affiliation>Aswan universirty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f Sallam, md</last_name>
    <phone>+20102435461</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w Shady, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hanygyne@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany F Sallam, MD</last_name>
      <phone>0122336052</phone>
      <phone_ext>002</phone_ext>
      <email>hany.farouk@aswu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Nahla W Shady, MD</last_name>
      <phone>01092440504</phone>
      <phone_ext>002</phone_ext>
      <email>nahla.elsayed@aswu.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Previa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

